Valve replacement remains, even today, a procedure built around a compromise. No medical therapy can halt or reverse the degeneration of a compromised heart valve: once the dysfunction exceeds the tolerable hemodynamic threshold, the surgeon or the interventionalist is left with only two options—repair, when the underlying substrate allows it, or replacement with a prosthesis. And every available prosthesis carries a structural flaw that no incremental advance has yet managed to eliminate. It is in this unresolved space—between mechanical durability and biological compatibility, between fatigue resistance and the capacity to integrate with the organism—that silk fibroin is carving out a role that deserves to be described with precision, avoiding both premature enthusiasm and the dismissiveness of those who write off natural biomaterials as laboratory curiosities.
The inherent limitation of current prostheses
Cardiac surgery has for decades relied on two families of prostheses, and the choice between them is still today an exercise in risk management rather than clinical optimization. Mechanical valves, built from synthetic materials such as pyrolytic carbon, offer a durability measured in decades: their weakness is not fatigue of the material but the surface the blood encounters. Flow through a mechanical prosthesis generates shear stress and localized stasis that activate the coagulation cascade, imposing lifelong anticoagulant therapy on the patient, with the attendant burden of bleeding risk, monitoring requirements, and lifestyle constraints. Device durability, in other words, is paid for with a systemic fragility of the patient.
Biological prostheses arose precisely as a response to this problem. Derived almost always from bovine pericardium or porcine aortic valves, they offer a more physiological hemodynamic profile and free the vast majority of recipients from the need for permanent anticoagulation. For at least two decades they have become the prevailing choice, supported as well by the spread of transcatheter procedures, which interface more readily with biological tissue. Their weak point, however, is equally structural and far more insidious: durability. The useful life of a bioprosthesis falls on average between ten and fifteen years, beyond which structural valve degeneration sets in—a process that progressively compromises the mechanics of the leaflets until functional failure and the need for reintervention.
Glutaraldehyde fixation and its hidden cost
To understand why a bioprosthesis degenerates, one has to go back to the way it is manufactured. Raw xenogeneic tissue would be rapidly recognized and degraded by the recipient's immune system; to make it implantable, it is chemically stabilized through glutaraldehyde fixation, which creates crosslinks between the collagen fibers and partially masks the antigenicity of the material. This solution, adopted as the standard since the 1960s, solves one problem and generates several others.
Residual aldehyde groups, not fully consumed by the crosslinking, remain free to bind circulating calcium ions and trigger a mineralization process that deposits hydroxyapatite within the collagen bundles of the leaflets. The crosslinking itself alters the secondary structure of the proteins, increasing the tissue's affinity for calcium and progressively stiffening the leaflets, with loss of elasticity and the appearance of mechanical lesions. Added to this is a problem of cytotoxicity: the glutaraldehyde released from the tissue inhibits the growth of endothelial cells, preventing the prosthetic surface from being colonized by a functional endothelium. The result is a valve that remains biologically inert, exposed to plasma and lipid insudation and to macrophage invasion, deprived of any capacity to repair or remodel itself.
There is, moreover, the immunological dimension, long underestimated. Fixation reduces antigenicity but does not eliminate it: xenogeneic epitopes such as galactose-α-1,3-galactose and N-glycolylneuraminic acid remain exposed and provoke a measurable antibody response as early as the weeks following implantation, contributing to calcification and tissue deterioration. It is no coincidence that degeneration is particularly rapid in young patients, whose immune and metabolic reactivity accelerates a process the fixed tissue is not equipped to counter. And it is precisely in the young, in pediatric patients, and in congenital heart disease that the most radical limitation of current prostheses manifests without mediation: no available device is capable of growing along with the patient, condemning the youngest to a succession of reinterventions.
The tissue engineering paradigm
The logic guiding the most advanced research overturns the traditional approach. Instead of stabilizing dead tissue so that it survives as long as possible against the organism's assault, cardiac valve tissue engineering aims to provide a scaffold capable of being repopulated by the recipient's cells, of remodeling in vivo, and, ideally, of transforming into a living tissue that maintains, repairs, and grows itself. A scaffold of this kind—whether synthetic biodegradable, decellularized, or hybrid—should possess cardiovascular-grade mechanics, tolerate cyclic loading, and at the same time offer a surface that favors cell adhesion and the deposition of extracellular matrix. The stated goal is ambitious: a device that, by recellularizing and remodeling, eliminates the need for reintervention at its root.
The difficulty is that the requirements are in tension with one another. What is needed is a material robust enough to withstand the pressure gradient and the billions of opening-and-closing cycles a valve faces over a lifetime, yet also hospitable enough to cells and degradable with a kinetics compatible with the formation of neotissue. It is within this web of seemingly irreconcilable constraints that fibroin displays its credentials.
Fibroin as a cardiovascular platform
Fibroin is the structural protein that constitutes, together with the sericin that coats it, more than ninety-five percent of the filament produced by Bombyx mori. It is composed predominantly of glycine, alanine, and serine, a simple sequence that organizes itself into crystalline beta-sheet domains responsible for a tensile strength notably high for a material of protein origin. It is a biomaterial approved by the Food and Drug Administration for clinical use, sterilizable, biocompatible, and available in a range of formats—films, hydrogels, electrospun matrices, woven structures—that make it a versatile platform rather than a single product.
The trait that makes it interesting for the cardiovascular district is not, however, robustness alone. Fibroin possesses a tunable biodegradation: by acting on the crystalline structure content and on the processing parameters, one can govern the rate at which the material is resorbed, ideally matching it to the pace at which the recipient's cells build their own tissue. This is a decisive property for a scaffold designed to disappear, leaving behind an autologous valve, and it distinguishes fibroin from synthetic polymers, whose degradation often generates acidic and inflammatory byproducts that are difficult to control.
Hemocompatibility and endothelialization
A valve lives in constant contact with blood, and the surface the blood encounters determines much of the device's fate. Here fibroin expresses some of its most relevant qualities. Its amino acid composition, rich in glycine, alanine, and serine, gives it hydrophilicity along with anti-adhesive and antibacterial properties that translate into a reduced tendency toward thrombus formation. Platelet adhesion on fibroin films has proven comparable to that of polytetrafluoroethylene, the reference synthetic material for vascular applications, which places the protein on competitive ground with respect to established standards.
Even more important is its capacity to support the growth and colonization of endothelial cells. Endothelialization—the formation of a confluent endothelial layer on the blood-contacting surface—is the true factor guaranteeing long-term patency and the antithrombogenicity of a graft, and it is exactly what glutaraldehyde prevents in traditional bioprostheses. Fibroin, by contrast, offers a substrate that endothelial cells recognize and on which they proliferate, opening the way to a biologically active rather than inert surface. Where intrinsic hemocompatibility alone is not enough, the protein lends itself to targeted modifications: sulfation, covalent immobilization of heparin, or the incorporation of growth factors have been shown to prolong clotting times and accelerate endothelialization, offering the designer a surface that can be engineered to specification.
The question of calcification
If calcification is the mechanism that condemns traditional bioprostheses, resistance to this process is the proving ground on which any alternative must demonstrate its value. The data available on fibroin-based scaffolds are encouraging on precisely this front. Electrospun matrices obtained by blending fibroin with poly(l-lactide-co-ε-caprolactone) have shown, at optimal composition ratios, superior anti-calcification capacity, assessed through alkaline phosphatase activity and the expression of markers of osteogenic differentiation of valvular interstitial cells—that is, the very cells whose steering toward an osteoblastic phenotype drives the pathological mineralization of the leaflets. The fact that the composition of the scaffold can shift the balance toward cytocompatibility and away from calcification suggests that, unlike glutaraldehyde-fixed tissue, a fibroin-based construct can be designed not to trigger that degenerative pathway from the outset.
From fiber to tri-leaflet scaffold
Translating these properties into an implantable device almost always proceeds through electrospinning, a technique that allows fibroin to be deposited into nanofibrous networks mimicking the architecture of the native extracellular matrix, with smooth, uniform surfaces and mechanics approaching those required of a valve prosthesis. Because fibroin alone tends to produce rigid constructs, the dominant strategy is that of hybrid materials, in which the tensile strength of silk is coupled with the elasticity and controlled degradation of a polymeric partner.
The combinations explored are diverse and instructive. Blends of fibroin with poly(ester-urethane)urea have yielded nanofibrous scaffolds with properties suited to valvular application and low immunogenicity. More recently, a hybrid construct of fibroin and DegraPol has made it possible to finely calibrate the compromise between rigidity and elasticity: formulations with a minority share of fibroin in a predominantly elastic polymer matrix offered the most convincing balance, with tensile strength and strain values compatible with the cardiovascular environment. But the perhaps most significant finding of this line of research concerns the hydrodynamic test: tri-leaflet prototypes tested in a pulse duplicator showed orifice areas, pressure gradients, and closing dynamics equivalent to those of polymeric and bioprosthetic valves already approved under European standards. It is a result that moves fibroin from the terrain of laboratory promise to that of functional plausibility, because it demonstrates that a silk-based construct can behave, under conditions emulating physiological ones, like a clinically acceptable device.
- Xue Y. et al. Biofabrication of PLCL/silk fibroin scaffold for anti-calcification tissue engineered prosthetic valve.Biofabrication, 2021. DOI: 10.1088/1758-5090/abe13a
- Three-dimensional silk fibroin/poly(ester-urethane) urea nanofibrous scaffold in heart valve tissue engineering.Applied Surface Science, 2018.
- Deon M. et al. Silk Fibroin/DegraPol: A Biohybrid Polymer for Biodegradable Electrospun Cardiovascular Substitutes. Advances in Materials Science and Engineering, 2025. DOI: 10.1155/amse/5097361
- Advancements and Perspectives in the Bioprosthetic Heart Valve: Biomaterial Processing and Emerging Polymeric Materials. Journal of the American Heart Association, 2025. DOI: 10.1161/JAHA.125.043061
- Senthil R. et al. Mechanisms and Drug Therapies of Bioprosthetic Heart Valve Calcification. Frontiers in Pharmacology, 2022. PMC9204043
- The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. Nature Biomedical Engineering, 2022. PMC8863575
- Chen L. et al. Improved Hemocompatibility and Endothelialization of Vascular Grafts by Covalent Immobilization of Sulfated Silk Fibroin on PLGA Scaffolds. Biomacromolecules, 2011. DOI: 10.1021/bm200479f
- Biomimetic bilayer hydrogel coating with antithrombotic and anticalcification properties for cardiovascular tissue engineering. Regenerative Biomaterials, 2025. PMC12869794
- Cordelle J., Mantero S. Insight on the endothelialization of small silk-based tissue-engineered vascular grafts. The International Journal of Artificial Organs, 2020. DOI: 10.1177/0391398820906547
